ArticlePloS one2026
A comparative analysis of ACE Inhibitors and ARBs as cancer risk factors.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceAngiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed antihypertensive agents. Although their cardiovascular and renal benefits are well established, uncertainty remains regarding their long-term associations with cancer risk.
objectiveTo compare cancer incidence among patients treated exclusively with ACEIs or ARBs in a large population-based cohort with long-term follow-up. DESIGN, SETTING, AND
participantsRetrospective cohort study using electronic health records from Clalit Health Services, Israel's largest healthcare organization. The source population included hypertensive adults aged 40 years or older who were free of cancer on January 1, 2000 (n = 1,048,575). After applying eligibility criteria and excluding patients who switched between treatment groups or were non-compliant with therapy, the final analytic cohort included 346,405 exclusive ACEI users and 77,018 exclusive ARB users. EXPOSURE: Exclusive treatment with either ACEIs or ARBs. Cancer incidence analyses were conducted during an active follow-up period from 2002 through 2024, allowing for a two-year exposure window. MAIN OUTCOMES AND MEASURES: The primary outcome was diagnosis of any cancer. Secondary outcomes included the ten most prevalent cancer types diagnosed during follow-up. Cancer incidence rates, odds ratios (ORs), age at diagnosis, and time from treatment initiation to cancer diagnosis were compared between treatment groups after adjustment for age, sex, and exposure duration.
resultsDuring follow-up, overall cancer incidence differed between treatment groups. ACEI therapy was associated with lower overall odds of cancer than ARB therapy. Associations varied across specific cancer types, with lower odds observed among ACEI users for several common malignancies, whereas no meaningful difference was observed for leukemia. Differences in age at diagnosis and time to diagnosis were also observed between treatment groups. CONCLUSIONS AND RELEVANCE: In this large population-based cohort, long-term cancer risk differed between patients treated exclusively with ACEIs and those treated exclusively with ARBs. While the observational design precludes causal inference, the findings contribute to the ongoing evaluation of the long-term oncologic safety profiles of RAAS-modulating therapies. Further prospective and mechanistic studies are needed to clarify the biological basis and clinical significance of these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.